Management of Anaplastic Large Cell Lymphoma.

Hematology/oncology clinics of North America 2017 Vol.31(2) p. 209-222

Chihara D, Fanale MA

관련 도메인

Abstract

Anaplastic large cell lymphoma (ALCL) is one of the most common peripheral T-cell lymphomas, and the incidence is higher in blacks than non-Hispanic whites. ALK-positive and ALK-negative ALCL are distinct subtypes that have different characteristics and clinical outcomes. Breast implant-associated ALCL is a rare lymphoma that has a good survival outcome, and a recent study showed that total capsulectomy is essential for treatment. Brentuximab vedotin (BV) is a standard treatment for relapsed/refractory ALCL. The response rate is high at 80-90%; however, once the disease progresses in patients on BV, survival outcome is very poor, with a median overall survival of less than two months.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
합병증 anaplastic large cell lymphoma 보형물연관 역형성대세포림프종 dict 2
해부 breast 유방 dict 1
약물 Brentuximab vedotin C2973446
brentuximab vedotin
scispacy 1
질환 Anaplastic C0205618
Undifferentiated
scispacy 1
질환 large cell lymphoma C0024302
Reticulosarcoma
scispacy 1
질환 ALCL → Anaplastic large cell lymphoma C0206180
Ki-1+ Anaplastic Large Cell Lymphoma
scispacy 1
질환 peripheral T-cell lymphomas C0079774
Peripheral T-Cell Lymphoma
scispacy 1
질환 ALK-positive C4290023
ALK Positive
scispacy 1
질환 ALK-negative ALCL scispacy 1
질환 Breast implant-associated ALCL scispacy 1
질환 lymphoma scispacy 1
기타 patients scispacy 1

MeSH Terms

Breast Implants; Brentuximab Vedotin; Disease-Free Survival; Female; Humans; Immunoconjugates; Lymphoma, Large-Cell, Anaplastic; Male; Survival Rate

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문